New England Journal of Medicine Publishes Results of Ebola Clinical Trial Confirming Superiority of Regeneron's REGN-EB3 to ZMapp in Preventing Ebola Deaths
TARRYTOWN, N.Y., Nov. 27, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that the New England Journal of Medicine(NEJM) published results from the randomized controlled PALM trial showing that Regeneron ' s... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 27, 2019 Category: Pharmaceuticals Source Type: clinical trials

Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC
Condition:   Ebola Virus Disease Intervention:   Biological: Ad26.ZEBOV, MVA-BN-Filo vaccine Sponsors:   London School of Hygiene and Tropical Medicine;   Epicentre;   Ministère de la Santé de la RDC;   Médecins Sans Frontières, France;   Coalition for Epidemic Preparedness Innovations;   Janssen Vaccines & Prevention B.V.;   Public Health England Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 5, 2019 Category: Research Source Type: clinical trials